title: Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities.
abstract: A recent large civilian randomized controlled trial on the use of tranexamic acid (TXA) for trauma reported important survival benefits. Subsequently, successful use of TXA for combat casualties in Afghanistan was also reported. As a result of these promising studies, there has been growing interest in the use of TXA for trauma. Potential adverse effects of TXA have also been reported. A US Department of Defense committee conducted a review and assessment of knowledge gaps and research requirements regarding the use of TXA for the treatment of casualties that have experienced traumatic hemorrhage. We present identified knowledge gaps and associated research priorities. We believe that important knowledge gaps exist and that a targeted, prioritized research effort will contribute to the refinement of practice guidelines over time.
authors.affiliation: US Army Medical Research and Materiel Command, Fort Detrick, Maryland 21702, USA. anthony.pusateri@amedd.army.mil
authors.forename: Anthony E
authors.initials: AE
authors.lastname: Pusateri
authors.forename: Richard B
authors.initials: RB
authors.lastname: Weiskopf
authors.forename: Vikhyat
authors.initials: V
authors.lastname: Bebarta
authors.forename: Frank
authors.initials: F
authors.lastname: Butler
authors.forename: Ramon F
authors.initials: RF
authors.lastname: Cestero
authors.forename: Irshad H
authors.initials: IH
authors.lastname: Chaudry
authors.forename: Virgil
authors.initials: V
authors.lastname: Deal
authors.forename: Warren C
authors.initials: WC
authors.lastname: Dorlac
authors.forename: Robert T
authors.initials: RT
authors.lastname: Gerhardt
authors.forename: Michael B
authors.initials: MB
authors.lastname: Given
authors.forename: Dan R
authors.initials: DR
authors.lastname: Hansen
authors.forename: W Keith
authors.initials: WK
authors.lastname: Hoots
authors.forename: Harvey G
authors.initials: HG
authors.lastname: Klein
authors.forename: Victor W
authors.initials: VW
authors.lastname: Macdonald
authors.forename: Kenneth L
authors.initials: KL
authors.lastname: Mattox
authors.forename: Rodney A
authors.initials: RA
authors.lastname: Michael
authors.forename: Jon
authors.initials: J
authors.lastname: Mogford
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Montcalm-Smith
authors.forename: Debra M
authors.initials: DM
authors.lastname: Niemeyer
authors.forename: W Keith
authors.initials: WK
authors.lastname: Prusaczyk
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Rappold
authors.forename: Todd
authors.initials: T
authors.lastname: Rassmussen
authors.forename: Francisco
authors.initials: F
authors.lastname: Rentas
authors.forename: James
authors.initials: J
authors.lastname: Ross
authors.forename: Christopher
authors.initials: C
authors.lastname: Thompson
authors.forename: Leo D
authors.initials: LD
authors.lastname: Tucker
mesh_terms: D000933:Antifibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D011183:Postoperative Complications / Q000139:chemically induced; D016032:Randomized Controlled Trials as Topic; D012106:Research; D012307:Risk Factors; D012640:Seizures / Q000139:chemically induced; D013927:Thrombosis / Q000139:chemically induced; D014148:Tranexamic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D014947:Wounds and Injuries / Q000188:drug therapy* / Q000601:surgery
chemical_list: D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid